As of 2025-09-17, the EV/EBITDA ratio of Nektar Therapeutics (NKTR) is -4.81. EV/EBITDA ratio is calculated by dividing the enterprise value by the TTM EBITDA. NKTR's latest enterprise value is 658.31 mil USD. NKTR's TTM EBITDA according to its financial statements is -136.89 mil USD. Dividing these 2 quantities gives us the above NKTR EV/EBITDA ratio.
Note: valuation result may not be accurate due to the company's negative EBITDA.
| Range | Selected | |
| Trailing P/E multiples | 7.6x - 15.3x | 11.6x |
| Forward P/E multiples | 12.1x - 15.9x | 14.6x |
| Fair Price | (114.97) - (145.94) | (124.52) |
| Upside | -330.5% - -392.5% | -349.6% |
| Date | EV/EBITDA |
| 2025-09-15 | -4.72 |
| 2025-09-12 | -4.68 |
| 2025-09-11 | -4.53 |
| 2025-09-10 | -4.63 |
| 2025-09-09 | -4.67 |
| 2025-09-08 | -4.24 |
| 2025-09-05 | -3.81 |
| 2025-09-04 | -3.38 |
| 2025-09-03 | -2.62 |
| 2025-09-02 | -2.67 |
| 2025-08-29 | -2.75 |
| 2025-08-28 | -2.70 |
| 2025-08-27 | -2.69 |
| 2025-08-26 | -2.64 |
| 2025-08-25 | -2.47 |
| 2025-08-22 | -2.46 |
| 2025-08-21 | -2.56 |
| 2025-08-20 | -2.45 |
| 2025-08-19 | -2.43 |
| 2025-08-18 | -2.50 |
| 2025-08-15 | -2.49 |
| 2025-08-14 | -2.43 |
| 2025-08-13 | -2.33 |
| 2025-08-12 | -2.11 |
| 2025-08-11 | -1.99 |
| 2025-08-08 | -2.05 |
| 2025-08-07 | -1.92 |
| 2025-08-06 | -1.99 |
| 2025-08-05 | -2.00 |
| 2025-08-04 | -2.08 |
| 2025-08-01 | -2.04 |
| 2025-07-31 | -1.91 |
| 2025-07-30 | -1.95 |
| 2025-07-29 | -2.04 |
| 2025-07-28 | -2.11 |
| 2025-07-25 | -2.25 |
| 2025-07-24 | -2.21 |
| 2025-07-23 | -2.25 |
| 2025-07-22 | -2.20 |
| 2025-07-21 | -2.23 |
| 2025-07-18 | -2.25 |
| 2025-07-17 | -2.42 |
| 2025-07-16 | -2.16 |
| 2025-07-15 | -2.13 |
| 2025-07-14 | -2.19 |
| 2025-07-11 | -2.25 |
| 2025-07-10 | -2.26 |
| 2025-07-09 | -2.08 |
| 2025-07-08 | -2.02 |
| 2025-07-07 | -2.10 |